<DOC>
	<DOCNO>NCT01866800</DOCNO>
	<brief_summary>Evaluating whether force diuresis match hydration reduce risk contrast induce nephropathy patient undergo Transcatheter Aortic Valve Implantation ( TAVI ) .</brief_summary>
	<brief_title>The Effect Forced Diuresis With Matched Hydration Reducing Acute Kidney Injury During TAVI</brief_title>
	<detailed_description>Reducing Acute Kidney Injury TAVI Patients ( REDUCE trial ) The Effect Forced Diuresis With Matched Hydration Reducing Acute Kidney Injury During Transcatheter Aortic Valve Implantation ( TAVI ) Interventional Cardiology , Department Cardiology Tel Aviv Medical Center Tel Aviv Sackler Faculty Medicine , Tel Aviv University Introduction Hypothesis : RenalGuard system reduce incidence acute kidney injury TAVI patient . Aim : To assess efficacy treatment RenalGuard system compare common practice use infusion normal saline N-acetylcysteine . Study population Patients undergoing trans-femoral TAVI . Study design Randomized Placebo control Single Blind Prospective study . Stages study : After sign informed consent , patient undergo follow baseline assessment Prestudy exam- 1 . Physical examination medical interview 2 . Cardiac echocardiogram assess systolic diastolic function well valvular function 3 . Endothelial function use EndoPat® system- non invasive method assess endothelial function . 4 . Carotid artery ultrasound Doppler include Intima Media Thickness calculation 5 . Cardiac Echo 6 . Blood tests- see description Each Patient provide 40cc blood follow blood test : 1 . Full chemistry include lipid level , thyroid function , BNP , NT-BNP , HbA1c , uric acid , glucose level 2 . Blood count 3 . Inflammatory biomarker ( hs-CRP , fibrinogen , IL-6 , IL-1 , MMP , Lp-PLA2 , procalcitonin , IL-10 , IL-35 , TNFa , AchE , cholinergic status , etc . ) 4 . Renal function marker : Creatinine , NGAL ( neutrophil gelatinase associate lipocalin , FGF23 , Cystatin-C. Urine albumin-Creatinine ratio 5 . Endothelial function marker : I-CAM , V-CAM , superoxide dismutase ADMA , oxidize LDL , etc 6 . Serum sample HPLC analysis contrast medium concentration . 7 . Serum sample frozen future test Urine sample take basic urinalysis , creatinine , albumin , microalbumin , electrolytes HPLC analysis contrast medium . Catheterization procedure subsequent medical therapy : All patient undergo trans-femoral aortic valve implantation per standard clinical practice . Briefly , femoral artery access standard endovascular technique involve advance large catheter ( 18 Fr ) aortic arch , retrogradely cross aortic valve , follow balloon valvuloplasty stent-valve implantation . During procedure , patient receive analgesic anxiolytic per protocol . Post procedural pharmacotherapy , sheath removal , deployment hemostatic device leave discretion attend physician . Following treatment catheterization laboratory , medical treatment throughout hospitalization follow treatment leave discretion treat physician manage patient care hospital ward . Specific agent add withdrawn make treat physician influence study team . Prevention contrast-induced nephropathy Each patient randomize one follow treatment strategy : Group 1-Isotonic saline rate 0.5- 1 mL/kg per hour administer begin 12 hour prior procedure , continue 12 hour contrast administration . In addition , 1200 mg N-acetyl-cysteine administer orally twice daily day day procedure . The patient connect Renal Guard System activate ( passive mode ) describe : Before procedure : - A standard 18-22 gauge catheter insert peripheral vein arm ( perform routinely TAVI procedure ) . - A standard Foley catheter place bladder urine collection ( perform routinely TAVI procedure ) . - The IV line urinary catheter connect RenalGuard System . - The RenalGuard System set 0 % match - i.e . urine rate volume measure deliver matched IV normal saline . ( Diagram A ) . - The system compute deliver continue IV normal saline rate 100 cc/hr ( 100cc/hr routine average fluid infusion rate TAVI procedure ) - During procedure , additional IV fluid add need accord clinical decision anesthesiologist attend physician . Procedure ( Diagram B ) : - Routine IV bolus give procedure . - Routine IV Furosemide give procedure . - The urine infusion volume measure RenalGuard system throughout catheterization procedure 6 h last contrast dose . - investigator analyze quantity quality urine duration procedure Group 2-Treatment group 1 addition , Renal Guard system activate describe . Before procedure : - A standard 18-22 gauge catheter insert peripheral vein arm ( perform routinely TAVI procedure ) . - A standard Foley catheter place bladder urine collection ( perform routinely TAVI procedure ) . - The IV line urinary catheter connect RenalGuard System . - The RenalGuard System set 100 % match - i.e . urine rate volume measure system deliver volume IV normal saline match volume urine produce patient.. ( Diagram A ) . Procedure ( Diagram B ) : - ~90 min procedure , initial IV bolus ( 250 ml ) normal saline 30 min . In patient heart failure volume bolus reduce 150ml . - Furosemide administer single intravenous bolus 0.25-0.5 mg/kg ( maximum 50 mg ) - When urine output rate &gt; 300 ml/h achieve , patient send catheterization laboratory . - Additional dos furosemide ( maximal cumulative dose 2.0 mg/kg ) give case urine output 300 ml/h treatment . - Matched hydration continue throughout catheterization procedure 6 h last contrast dose . - investigator analyze quantity quality urine duration procedure . Diagram A - The `` RenalGuard '' System Definition AKI . Serum creatinine level measure prior TAVI 48-72 hr post procedure . AKI define stage 1 , 2 3 accord VARC-2 AKI classification16 ( table 1 ) . Table 1 . - AKI post TAVI accord VARC-2 classification Acute Kidney Injury post TAVI Stage 1 Increase serum creatinine 150-199 % baseline OR Increase ≥0.3 mg/dl ( 26.4 mmol/L ) OR Urine output &lt; 0.5 ml/kg/h &gt; 6 &lt; 12 h Stage 2 Increase serum creatinine 200-299 % baseline OR Urine output &lt; 0.5 ml/kg/h &gt; 12 &lt; 24 h Stage 3 Increase serum creatinine ≥ 300 % baseline OR Increase serum creatinine ≥4.0 mg/dL ( 354 mmol/L ) acute increase least 0.5 mg/dl ( 44 mmol/l ) OR Urine output &lt; 0.3 ml/kg/h &gt; 24 h OR Anuria &gt; 12 h Follow Up After procedure , patient follow clinically well use laboratory test . The follow procedure detail table . Blood urinary sample hospitalization : Blood sample : - Taken baseline ( admission ) , procedure , 6 hour , 12 hour , 24 hour , 48 hour , 72 hour post procedure . - investigator evaluate following : full chemistry BNP , NT-BNP , uric acid , blood count , inflammatory biomarker ( hs-CRP , fibrinogen , IL-6 , IL-1 , MMP , Lp-PLA2 , procalcitonin , IL-10 , IL-35 , TNFa , AchE , cholinergic status , etc . ) , renal marker ( creatinine , NGAL ( neutrophil gelatinase associate lipocalin , FGF23 , Cystatin-C ) , serum sample HPLC analysis contrast medium concentration serum sample frozen future test Urine sample : - Taken baseline ( admission ) , procedure , 6 hour , 12 hour , 24 hour , 48 hour , 72 hour post procedure . - In every sample -50 cc urine draw measure : basic urinalysis , , electrolytes , protein creatinine , HPLC analysis contrast medium . Primary objective : 1 . Reduction acute kidney injury ( stage 1 ) 48-72 hour . Secondary objective : 1 . To determine whether endothelial function assessment predict AKI . 2 . To determine laboratory test predict AKI high risk population . 3 . To determine whether chronic statin treatment offer clinical benefit prevent contrast induce nephropathy . 4 . To determine carotid Doppler analysis predict AKI occurrence . 5 . To determine predictive value different biomarkers assess clinical outcome TAVI patient . 6 . To assess whether RenalGuard system lower Major adverse clinical event ( MACE ) define composite all-cause mortality , myocardial infarction , AKI , 30 day readmission rate , dialysis . 7 . To assess whether RenalGuard system lower 30 day readmission rate 8 . To assess whether RenalGuard system lower 30 day congestive heart failure exacerbation rate 9 . Safety RenalGuard system 30 day . Key inclusion criterion 1 . Subject 65 year old able willing give inform consent . 2 . Patients undergo plan trans-femoral TAVI . 3 . Calculated eGFR 60ml/min/1.73m2 ( MDRD ) Key exclusion criterion 1 . History acute coronary syndrome past 30 day . 2 . History congest heart failure leave ventricular ejection fraction &lt; 30 % exacerbation past 30 day . 3 . Current dialysis treatment . 4 . Known furosemide hypersensitivity . 5 . Contraindications placement Foley catheter bladder . Sample size 110 patient trial arm ( 220 total ) Our center perform 200 procedure annually . The anticipated recruitment rate approximately 110 patient annually . Statistical justification sample size Under assumption AKI relatively common ( 40 % ) TAVI , RenalGuard system show reduce incidence AKI 50 % 14 , 15 , number patient need group attain 80 % power alpha 0.05 , 92. investigator plan recruit 110 patient group order assure achieve statistical power . Planned statistical analysis Standard statistical analysis use compare aforementioned endpoint study arm . investigator compare incidence AKI clinical difference group . Between-group comparison clinical endpoint , biomarkers , image data perform use Mann-Whitney U , independent Student 's test , CHI square test accord distribution variable . All value express median interquartile range non-normally distribute continuous variable mean standard error mean ( SEM ) normally distribute variable . Reported p value two-sided , p &lt; 0.05 consider statistically significant . All analysis perform use SPSS statistical software .</detailed_description>
	<mesh_term>Acute Kidney Injury</mesh_term>
	<mesh_term>Aortic Valve Stenosis</mesh_term>
	<mesh_term>Heart Defects , Congenital</mesh_term>
	<mesh_term>Heart Valve Diseases</mesh_term>
	<mesh_term>Acetylcysteine</mesh_term>
	<mesh_term>N-monoacetylcystine</mesh_term>
	<criteria>1 . Subject 65 year old able willing give inform consent . 2 . Patients undergo planned transfemoral TAVI . 3 . Calculated eGFR 60ml/min/1.73m2 ( MDRD ) 1 . History acute coronary syndrome past 30 day . 2 . History congest heart failure leave ventricular ejection fraction &lt; 30 % exacerbation past 30 day . 3 . Current dialysis treatment . 4 . Known furosemide hypersensitivity . 5 . Contraindications placement Foley catheter bladder .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>TAVI</keyword>
	<keyword>TAVR</keyword>
	<keyword>CIN</keyword>
	<keyword>AKI</keyword>
</DOC>